# Antengene Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antengene-corporation

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.antengene.com
- Total disclosed funding: $238M
- Latest round: Series C (Jul 19, 2020)
- Investors on record: 12

## About

Founded in 2016 and based in Shanghai, China, Antengene Corporation Limited operates as a biopharmaceutical company that develops medicines for cancer treatment. Antengene Corporation has five clinical-stage products under research and development for relapsed/refractory multiple myeloma, lymphomas, solid tumors and multiple cancer types.

## Funding rounds

- Series C, Jul 19, 2020, $97M — Qiming Venture Partners, Fidelity Investments, Boyu Capital, GL Ventures, GIC
- Series B, Jan 2, 2019, $120M — Qiming Venture Partners, FountainVest, Celgene, Boyu Capital, Taikang, TF Capital, Wuxi AppTec Group
- Series A, Aug 16, 2017, $21M — Qiming Venture Partners, Huagai Capital, TF Capital, Tigermed

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- TF Capital — Series A, Series B
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A
- FountainVest (https://capitalatlas.ai/funds/fountainvest) — Series B
- Celgene — Series B
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series B, Series C
- Taikang — Series B
- Wuxi AppTec Group — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series C
- GIC — Series C